Mometasone Furoate (Mometasone Furoate Monohydrate)

Mometasone furoate, the active ingredient in this product, is a corticosteroid presented as a nasal spray for nasal use. It treats allergic rhinitis and related nasal inflammation in adults and children as directed by a healthcare professional.

GNH USA supplies Mometasone furoate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate is a topical corticosteroid used in the nasal cavity to manage inflammatory nasal conditions.

- Seasonal allergic rhinitis: reduces sneezing, itching, and nasal congestion during pollen seasons. - Perennial allergic rhinitis: alleviates chronic nasal symptoms caused by year‑round allergens. - Nasal polyps: helps shrink polyps and improve airflow, reducing the need for surgery.

Mometasone furoate may cause local and systemic adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleeds). - Throat dryness. - Cough. - Unpleasant taste.

Serious or Rare Side Effects: - Nasal septal perforation. - Secondary infections such as fungal sinusitis. - Elevated intraocular pressure or glaucoma. - Adrenal suppression with prolonged high‑dose use. - Systemic corticosteroid effects (e.g., hyperglycemia, osteoporosis) in susceptible patients.

Before using mometasone furoate nasal spray, consider the following safety measures.

- Pregnancy: consult a healthcare provider; safety data are limited. - Breastfeeding: discuss potential risks with a clinician. - Existing infections: avoid use if active nasal or sinus infections are present. - Surgery: discontinue prior to nasal or sinus surgery to reduce bleeding risk. - Long‑term use: monitor for signs of adrenal suppression or ocular pressure changes. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medications, affecting efficacy or safety.

Major Interactions (Avoid): - Systemic CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic corticosteroid exposure. - Nasal decongestant sprays: concurrent use can increase risk of nasal mucosa irritation.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole): may modestly raise systemic levels. - Antihistamines: may enhance overall antihistaminic effect, requiring symptom monitoring. - Immunosuppressants: combined use may increase infection risk.